Clinical trials: Phase 2
Breast Cancer
Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
The need to understand LABC is especially compelling in populations and countries with limited resources, where breast cancer incidence is relatively low, but mortality is comparably high.
- Trial name
- NCT02280252
- Testing
- Paclitaxel, Radiation therapy
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- NYU Langone Health
Covid19 Vaccine
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study
The purpose of this study is to assess the safety and immunogenicity of MVC-COV1901 vaccine who are generally healthy or with stable pre-existing health conditions and have received 2 doses of Placebo in the main study CT-COV-21
- Trial name
- NCT05048849
- Testing
- MVC-COV1901(S protein with adjuvant)
- Where
- 11 sites in Taiwan
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
Ovarian Cancer
Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
This study aims to investigate the safety and efficacy of combination therapy of Fluzoparib combined With Dalpiciclib for platinum-resistant recurrent ovarian cancer through a single-center, prospective, single-arm, phase II…
- Trial name
- NCT06552858
- Testing
- Fluzoparib, Dalpiciclib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Uterine Fibroids
Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
Two (2) dose levels of Proellex or placebo will be administered once-daily for up to 91 days. Following screening and a pre-treatment endometrial biopsy, subjects will be followed monthly for the three month treatment phase.
- Trial name
- NCT00882258
- Testing
- 12.5 mg Proellex, 25 mg Proellex
- Where
- 16 sites in United States
- Volunteers
- 144 people
- Sponsor
- Repros Therapeutics Inc.
Colon Prep for Colonoscopy
Safety and Efficacy Study of an Edible Colonoscopy Preparation
The purpose of this study is to evaluate the efficacy and safety of ECP (PEG 3350) Colon Prep Kit compared with MoviPrep split-dose as a colon-cleansing preparation for colonoscopy.
- Trial name
- NCT03332485
- Testing
- ECP Colon Prep Kit, MoviPrep®
- Where
- 8 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sebela Pharmaceuticals Development LLC
COVID-19
The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19
The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 120 mg versus placebo once daily administration with standard of care therapy for 14 days (maximum up to 21 days) in patients with moderate…
- Trial name
- NCT04347915
- Testing
- Clevudine
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Bukwang Pharmaceutical
Chronic Myeloid Leukemia, Chronic Phase
Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
This study aims at evaluating the efficacy of treatment with ponatinib in patients with chronic myeloid leukemia who are in a chronic phase and who previously received treatment with imatinib but resulted to be resistant to it.
- Conditions
- Chronic Myeloid Leukemia, Chronic Phase, Adults
- Trial name
- NCT02398825
- Testing
- Ponatinib
- Where
- 37 sites in Italy
- Volunteers
- 14 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Sarcoma
Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining chemotherapy with surgery may kill more tumor cells.
- Trial name
- NCT00003776
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer Female, Ovarian Cancer
Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients
Safety and tolerability of combination of Nivolumab and Ipilimumab will be studied in patients with 3 different types of cancers in 3 parts of the study, as shown below: Part 1 - Neoadjuvant Therapy of Breast Cancer; Part 2 …
- Conditions
- Breast Cancer Female, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03342417
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- ExcellaBio LLC
Head and Neck Neoplasms
Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors
This study will investigate the efficacy and safety of recombinant human endostatin adenovirus combined with chemotherapy for advanced head and neck malignant tumors.
- Trial name
- NCT02283489
- Testing
- recombinant human endostatin adenovirus, Cisplatin injection, Paclitaxel injection
- Where
- 4 sites in China
- Volunteers
- 180 people
- Sponsor
- Renmiao Zhang
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This randomized phase II trial studies how well bevacizumab with or without everolimus works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT00886691
- Testing
- Bevacizumab, Everolimus, Laboratory Biomarker Analysis
- Where
- 45 sites in United States
- Volunteers
- 150 people
- Sponsor
- GOG Foundation
Locally Advanced Head-and-Neck Cancer
Carbon Ion Re-Radiotherapy in Patients With Recurrent or Progressive Locally Advanced Head-and-Neck Cancer
After multimodal therapy of head-and-neck tumors, patients often develop local recurrence, locally progressive disease or second primary tumors. In this highly pre-treated patient cohort, therapeutic options are limited.
- Trial name
- CARE (NCT04185974)
- Testing
- C12 re-irradiation, Photon re-irradiation
- Where
- 2 sites in Germany
- Volunteers
- 72 people
- Sponsor
- University Hospital Heidelberg
Melanoma
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in subjects with previously untreated metastatic…
- Trial name
- NCT00107718
- Testing
- SB-485232
- Where
- 20 sites in United States, Australia
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Immunotherapy
Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy
PROMIT is a single arm phase 2 trial evaluating the clinical activity of immune checkpoint blockade (ICB) after administration of dacarbazine (DTIC) in patients with unresectable or metastatic, BRAF wildtype melanoma with primary…
- Trial name
- PROMIT (NCT04225390)
- Testing
- Dacarbazine (DTIC)
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Breast Cancer, Lymphedema
Hyperbaric Oxygen Therapy Compared With Standard Therapy in Treating Chronic Arm Lymphedema in Patients Who Have Undergone Radiation Therapy for Cancer
RATIONALE: Hyperbaric oxygen therapy may be effective in repairing damaged tissue and reducing lymphedema caused by radiation therapy for cancer.
- Conditions
- Breast Cancer, Lymphedema, Perioperative/Postoperative Complications, Radiation Fibrosis
- Trial name
- NCT00077090
- Testing
- hyperbaric oxygen
- Where
- 5 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Small Cell Lung Cancer
Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
- Trial name
- NCT04830813
- Testing
- Chiauranib
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Hepatocellular Carcinoma
Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
This is a phase II, open-label study to evaluate the efficacy and safety of Durvalumab plus Lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT05312216
- Testing
- Durvalumab plus Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhejiang University
DLBCL
Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older
This study evaluate the efficacy of Tafasitamab and Lenalinomide associated to Rituximab in elderly patients with frontline Diffuse Large B-Cell Lymphoma as assessed by the Overall Response Rate (ORR) after 3 cycles of treatment…
- Trial name
- NCT04974216
- Testing
- Tafasitamab, Lenalidomide, Rituximab
- Where
- 20 sites in Belgium, France
- Volunteers
- 71 people
- Sponsor
- The Lymphoma Academic Research Organisation
Resectable Head and Neck Squamous Cell Carcinoma
Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to evaluate the anti-tumor activity, safety and tolerability of the combination of Sacituzumab govitecan and Tagitanlimab as neoadjuvant therapy in patients with resectable head and neck…
- Trial name
- NCT07492914
- Testing
- Sacituzumab Govitecan, Tagitanlimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- West China Hospital
NSCLC
Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations
Single-arm, open-label, multicenter phase II clinical study
- Trial name
- CVL009-2001 (NCT06029816)
- Testing
- Neratinib tablets
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.